A Phase I Clinical Study of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular Risk
A Randomized, Double-blind, Placebo-controlled, Single and Multiple-dose Administration, Dose-escalation Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic, Pharmacodynamics Characteristics and the Effect of Food on Pharmacokinetics of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular Risk
This study comprised of 3 parts, gradually investigating the safety, tolerance, PK and PD characteristics of the ZL-65 tablets in healthy adult participants and obesity with cardiovascular risk participants in Australia. The study results will provide important basis for formulating the subsequent study strategies and dosing plans.Part 1: Single-ascending Dose (SAD) study and Food Effect (FE) study;Part 2: Multiple-ascending Doses (MAD) study;Part 3: Obesity with cardiovascular risk study.
研究概览
地位
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Sun Haibin
- 电话号码:+8618200237928
- 邮箱:sunhaibin@zenitar.cn
学习地点
-
-
-
Melbourne、澳大利亚
- Nucleus Network Pty Ltd Commercial Road
-
接触:
- Ofer Gonen, Doctor
- 电话号码:03 8593 9801
- 邮箱:o.gonen@nucleusnetwork.com.au
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- i, Healthy adult participants, regardless of gender, aged between 18 and 65 years old when the informed consent is signed; ii,Male participants with a body weight of >= 50.0 kg, female participants with a body weight of >= 45.0 kg; iii, Those who can understand the informed consent form, voluntarily participate in the trial and sign the informed consent form.
Exclusion Criteria:
- Individuals with allergic constitution, or those with a history of clinically significant food, drug allergies or other allergic reactions as determined by the investigators; or those who are known to be allergic to NLRP3 inhibitors or to the excipient ingredients of the IP;
- Have any prior diagnosis of diabetes mellitus;
- Those with a positive result in any of the following tests: HIV antibody, syphilis spirochete antibody, hepatitis B surface antigen, hepatitis C antibody, or interferon-gamma release assay;
- Those who donated blood or lost blood >=400 mL within 30 days prior to screening, or received blood transfusion;
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Single-ascending Dose (SAD) study and Food Effect (FE) study
|
The SAD portion of the study consists of 5 cohorts. Dosing in these cohorts will precede sequentially: 5 mg, 10 mg, 25 mg, 40 mg and 50 mg cohorts. |
|
实验性的:Multiple-ascending Doses (MAD) study
|
The MAD portion of the study consists of 3 cohorts. Dosing in these cohorts will precede sequentially:10 mg, 25 mg and 40 mg cohorts. |
|
实验性的:Obesity with cardiovascular risk study
|
This study intends to set up 2 dose cohorts, temporarily as follows: 1) 10 mg QD cohort, 2) 25 mg QD cohort. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of adverse events
大体时间:Day 1 to Day 21
|
including hematology, blood biochemistry, urinalysis, and coagulation function |
Day 1 to Day 21
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
ZL65 Pharmacokinetics (PK):Cmax
大体时间:0-144 hours
|
0-144 hours
|
|
ZL65 Pharmacokinetics (PK):Tmax
大体时间:0-144 hours
|
0-144 hours
|
|
ZL65 Pharmacokinetics (PK):AUC0-t
大体时间:0-144 hours
|
0-144 hours
|
|
ZL65 Pharmacokinetics (PK):t1/2
大体时间:0-144 hours
|
0-144 hours
|
合作者和调查者
调查人员
- 首席研究员:Ofer Gonen, Doctor、Nucleus Network Pty Ltd Commercial Road
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.